Evidence map›Paper›PMID 35059969›Full record

ArticleMolecular biology reports2022

Identification of ribosomal protein L9 as a novel regulator of proinflammatory damage-associated molecular pattern molecules.

Masahiro Watanabe, Takao Toyomura, Hidenori Wake, Takashi Nishinaka, Omer Faruk Hatipoglu, Hideo Takahashi, Masahiro Nishibori, Shuji Mori

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Masahiro WatanabeDepartment of Pharmacology, School of Pharmacy, Shujitsu University, 1-6-1 Nishigawara, Naka-Ku, Okayama, 703-8516, Japan.
Takao ToyomuraDepartment of Pharmacology, School of Pharmacy, Shujitsu University, 1-6-1 Nishigawara, Naka-Ku, Okayama, 703-8516, Japan.
Hidenori WakeDepartment of Pharmacology, Faculty of Medicine, Kindai University, Osaka-Sayama, 589-8511, Japan.
Takashi NishinakaDepartment of Pharmacology, Faculty of Medicine, Kindai University, Osaka-Sayama, 589-8511, Japan.
Omer Faruk HatipogluDepartment of Pharmacology, Faculty of Medicine, Kindai University, Osaka-Sayama, 589-8511, Japan.
Hideo TakahashiDepartment of Pharmacology, Faculty of Medicine, Kindai University, Osaka-Sayama, 589-8511, Japan.
Masahiro NishiboriDepartment of Pharmacology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, 700-8558, Japan.
Shuji MoriDepartment of Pharmacology, School of Pharmacy, Shujitsu University, 1-6-1 Nishigawara, Naka-Ku, Okayama, 703-8516, Japan. morimori@shujitsu.ac.jp.ORCID http://orcid.org/0000-0002-2826-1937
Kindai University · JPShujitsu University · JPOkayama University · JP

Funding

Japan Society for the Promotion of Science 21K06657Japan Society for the Promotion of Science 21K06701
6 · The paper itself

Abstract

backgroundWe previously reported that advanced glycation endproducts (AGEs) increase the proinflammatory activity of high mobility group box-1 (HMGB1), a representative damage-associated molecular pattern molecule (DAMP), through their direct interaction. This suggested that AGEs activate other DAMPs and led us to search for novel DAMPs capable of interacting with AGEs. METHODS AND

resultsThe chromatographic analysis using AGE-immobilized gel revealed the ribosomal protein family to be a factor with binding activity to AGEs. Ribosomal protein L9 (RPL9), a member of the ribosomal protein family, was found in the centrifugal supernatant of ruptured cells and in the serum of lipopolysaccharide (LPS)-stimulated sepsis model mice, exhibiting similar characteristic properties to HMGB1. Although HMGB1 potentiated LPS-stimulated TNF-α expression in macrophage-like RAW264.7 cells, RPL9 hardly exhibited this activity. Of note, RPL9 significantly suppressed the potentiated mRNA expression and protein production of TNF-α by HMGB1 plus LPS stimulation, suggesting its regulatory roles in DAMP-induced proinflammatory activity. Based on the differential scanning fluorimetric analysis, the direct interaction between RPL9 and HMGB1 may play a role in the suppressive effects of RPL9.

conclusionsThis study suggested that RPL9 is a novel type of DAMP with a regulatory role in the proinflammatory response and provided insight into the pathophysiology of inflammatory diseases.

Indexed as

AlarminsRibosomal ProteinsAnimalsHMGB1 ProteinLipopolysaccharidesMiceRAW 264.7 CellsTumor Necrosis Factor-alphaAlarminsHMGB1 ProteinHMGB1 protein, mouseLipopolysaccharidesribosomal protein L9Ribosomal ProteinsTumor Necrosis Factor-alphaDamage-associated molecular pattern moleculesHigh mobility group box-1LipopolysaccharideRibosomal protein L9

Identifiers

PMID35059969
OpenAlexW4205359754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.